至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA1 variant

MedComm (2020). 2022-05; 
Zhongcheng Zhou, Peng Du, Ning Li, Xinxin Xiong, Shengjun Tang, Qinjin Dai, Taorui Wang, Meixing Yu, Miao Man, Kelvin Lam, Daniel T Baptista-Hon, Wa Hou Tai, Olivia Monteiro, Weng Sam Ng, Un Man Lee, Zhihai Liu, Kang Zhang, Gen Li
Products/Services Used Details Operation
Plasmid DNA Preparation … RBD ) were synthesized and subcloned into the pCAGGS vector (Genscript, Nanjing, China). The expression plasmid containing the spike gene with the D614G substitution was … Get A Quote

摘要

The SARS-CoV-2 Omicron BA.1 variant of concern contains more than 30 mutations in the spike protein, with half of these mutations localized in the receptor-binding domain (RBD). Emerging evidence suggests that these large number of mutations impact the neutralizing efficacy of vaccines and monoclonal antibodies. We investigated the relative contributions of spike protein and RBD mutations in Omicron BA.1 variants on infectivity, cell-cell fusion, and their sensitivity to neutralization by monoclonal antibodies or vaccinated sera from individuals who received homologous (CoronaVac, SinoPharm) or heterologous (CoronaVac-BNT162b2, BioNTech) and nonhuman primates that received a recombinant RBD protein vaccine. Our... More

关键词

Omicron BA.1, SARS‐CoV‐2, booster, neutralization, vaccine